XLO Stock — Xilio Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer. Leveraging our clinically-validated masking technology and capabilities, we are developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents.

Source: 10-K FY2025 via SEC EDGAR

Share price

$8.80

Market cap

$58.0M

Cash

$122.2M

Enterprise value

-$64.2M

Balance sheet

Cash	$122.2M
Debt	$0.0M
Net cash	$122.2M
Enterprise value	-$64.2M
Basic shares	7.1M shares
Fully diluted shares	17.4M shares
Fully diluted market cap	$153.0M
Cash per share	$17.31
Quarterly burn	$18.8M
Cash runway	7.3 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

6.6M

Pre-funded warrants

0.0M

Options

2.5M

RSUs

0.0M

Warrants

8.2M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.1M

FDSO

17.4M

Cap table as of 2026-03-18.

Price history

Loading XLO daily closes…

Loading price history…

Next catalyst

XTX501 · Est. Sep 30, 2027 · half midpoint · guided in 8 mo

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Sep 30, 2027 in 8 mo half midpoint	XTX501 Phase 1/2 trial of XTX501: initial Phase 1 data in metastatic non-small cell lung cancer · NCT07688577	Phase 1/2	metastatic non-small cell lung cancer	2H 2027
Oct 13 - Nov 24 in 23 mo	XTX301	Phase 1/2	Advanced Solid Tumor	—
Dec 13, 2029 - Jan 24, 2030 in 38 mo	XTX501	Phase 1/2	Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced Solid Tumor	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

efarindodekin alfa

Phase 2 · Active Modality: biologic (masked IL-12 immunotherapy)

Target IL-12

Partnerships Gilead Sciences: exclusive global license (Mar 2024; $30M upfront; $75M transition fee on opt-in after Phase 1 + initial Phase 2 data package; up to $500M milestones; high-single-to-mid-teens royalties)

Indications

Advanced solid tumors (Phase 2)

Catalysts

— H1 2027

Status note Ongoing Phase 2 monotherapy; Xilio conducts development through initial Phase 2.

vilastobart

Phase 2 · Active Modality: biologic (masked, Fc-enhanced anti-CTLA-4 monoclonal antibody)

Target CTLA-4

Partnerships Roche: 2023 co-funded clinical trial collaboration (clinical supply agreement; atezolizumab combination in MSS mCRC; $8M cost-sharing received)

Indications

Microsatellite stable metastatic colorectal cancer (with atezolizumab) (Phase 2)

Status note Phase 2 complete in MSS mCRC (without liver metastases); seeking partner to maximize value.

XTX501

Preclinical · Active Modality: biologic (bispecific PD-1 / masked IL-2 antibody fusion protein)

Target PD-1 / IL-2

Indications

Metastatic NSCLC and other solid tumors (Preclinical)

Catalysts

— mid-2026
— H2 2026
— H2 2027

Status note IND-enabling studies ongoing.

AbbVie collaboration program

Preclinical · Active Modality: biologic (masked antibody-based immunotherapy)

Partnerships AbbVie: Feb 2025 collaboration, license and option agreement for up to four masked immunotherapy programs ($42M upfront; up to ~$2.1B contingent; high-single/mid-single-digit royalties); plus Initial Option Program (masked T cell engagers) and up to two Additional Option Programs

Status note Collaboration program preclinical through lead generation; $5M and $6M development milestones achieved (Q4 2025, Q2 2026).

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05684965	Phase 1/2	Recruiting	Sponsor	Xilio Development, Inc.	—	Advanced Solid Tumor	—
NCT07688577	Phase 1/2	Not yet recruiting	Sponsor	Xilio Development, Inc.	—	Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced Solid Tumor	2H 2027 Est. Sep 30, 2027 · half midpoint
NCT07765836	Phase 2	Not yet recruiting	Collaborator	Massachusetts General Hospital	—	Pancreatic Cancer Metastatic	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Xilio Development, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	592,300	+592,300	0.11%	2026-08-14
Frazier Life Sciences	422,505	no change	0.09%	2026-08-14
Stonepine Capital	225,994	+161,832	1.65%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

XLO — Xilio Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

XLO — Xilio Therapeutics Inc.